By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vaccine developer Affiris will use Probiogen's Human Artificial Lymph Node Technology (HuALN) as an analytical tool to find targets for its Affitome vaccination project, Affiris said today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.